This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Efficacy of Eszopiclone With Mild to Moderate Obstructive Sleep Apnea Syndrome (OSAS)

This study has been completed.
Information provided by (Responsible Party):
Sunovion Identifier:
First received: May 23, 2008
Last updated: February 21, 2012
Last verified: February 2012
The purpose of this study is to evaluate the hypnotic efficacy of ezopiclone in subjects with mild to moderate OSAS.

Condition Intervention Phase
Obstructive Sleep Apnea Syndrome Drug: Eszopiclone Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: The Safety and Efficacy of Eszopiclone in Subjects With Mild to Moderate Obstructive Sleep Apnea Syndrome

Resource links provided by NLM:

Further study details as provided by Sunovion:

Primary Outcome Measures:
  • AHI (frequency of apnea and hypopnea episodes). [ Time Frame: Nights -14, 1, 2, 8, 9 ]

Secondary Outcome Measures:
  • The mean duration of apnea and hypopnea episodes [ Time Frame: Nights -14, 1, 2, 8, 9 ]
  • Oxygen saturation during apnea and hypopnea [ Time Frame: Nights -14, 1, 2, 8, 9 ]
  • The number of arousals during apnea and hypopnea [ Time Frame: Nights -14, 1, 2, 8, 9 ]
  • Objective sleep parameters as measured by PSG (i.e., latency to persistent sleep, sleep efficiency, and wake time after sleep onset [ Time Frame: Nights -14, 1, 2, 8, 9 ]

Enrollment: 20
Study Start Date: August 2003
Study Completion Date: January 2004
Primary Completion Date: January 2004 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: A
eszopiclone 3 mg QD
Drug: Eszopiclone
Eszopiclone 3 mg QD
Other Names:
  • Lunesta
  • (S)-Zopliclone
Placebo Comparator: B
placebo tablet
Drug: Placebo
Placebo tablet

Detailed Description:
Sleep apnea is a sleep disorder characterized by pauses in breathing during sleep. This study will compare the use of eszopiclone to placebo for subjects with mild to moderate obstructive sleep Apnea syndrome (OSAS). Frequency and duration of apnea and hypopnea episodes, oxygen saturation, objective sleep parameters and safety information will be collected in this study. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

Ages Eligible for Study:   35 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The subject is capable of understanding and complying with the protocol and has signed the informed consent document, including the privacy authorization. Female subjects of childbearing potential must sign the Women of Childbearing Potential Addendum to the informed consent form.
  • Male and female subjects between 35 and 64 years of age, inclusive, with mild to moderate obstructive sleep apnea syndrome (AHI range ≥10 and ≤40).
  • Females considered not of childbearing potential must be surgically sterile or greater than one-year post menopausal, defined as a complete cessation of menstruation for at least one year.
  • Subjects must use continuous positive airway pressure (CPAP).
  • Subjects must be in general good health based on screening physical examination (defined as the absence of any clinically relevant abnormalities), medical history, 12-lead ECG, and clinical laboratory values (hematology, serum chemistry and urinalysis).

Exclusion Criteria:

  • Subject has any clinically significant unstable medical abnormality, chronic disease, or a history of a clinically significant abnormality of the cardiovascular, respiratory, hepatic, or renal systems.
  • Subject has a history of, or current malignancy except for non melanomatous skin cancer.
  • Subject tests positive at screening for hepatitis B surface antigen or hepatitis C antibody, or the subject has a history of a positive result.
  • Subject is known to be seropositive for human immunodeficiency virus (HIV).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00685269

United States, Georgia
Atlanta, Georgia, United States
United States, Ohio
Cincinnati, Ohio, United States
Sponsors and Collaborators
  More Information

Responsible Party: Sunovion Identifier: NCT00685269     History of Changes
Other Study ID Numbers: 190-028
Study First Received: May 23, 2008
Last Updated: February 21, 2012

Keywords provided by Sunovion:
Obstructive Sleep Apnea Syndrome

Additional relevant MeSH terms:
Sleep Apnea Syndromes
Sleep Apnea, Obstructive
Pathologic Processes
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Nervous System Diseases
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs processed this record on August 18, 2017